You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study
|
|---|---|
| Published in |
BMC Cancer, January 2012
|
| DOI | 10.1186/1471-2407-12-16 |
| Pubmed ID | |
| Authors |
Carolyn D Britten, Antoinette S Gomes, Zev A Wainberg, David Elashoff, Rafael Amado, Yan Xin, Ronald W Busuttil, Dennis J Slamon, Richard S Finn |
| Abstract |
Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 17% |
| Unknown | 5 | 83% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 39 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 17% |
| Researcher | 7 | 17% |
| Other | 4 | 10% |
| Student > Doctoral Student | 3 | 7% |
| Professor > Associate Professor | 3 | 7% |
| Other | 8 | 20% |
| Unknown | 9 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 44% |
| Agricultural and Biological Sciences | 3 | 7% |
| Nursing and Health Professions | 2 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Other | 4 | 10% |
| Unknown | 11 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2012.
All research outputs
#12,852,556
of 22,661,413 outputs
Outputs from BMC Cancer
#2,705
of 8,239 outputs
Outputs of similar age
#141,439
of 243,441 outputs
Outputs of similar age from BMC Cancer
#32
of 82 outputs
Altmetric has tracked 22,661,413 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,239 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,441 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.